Phase II clinical evaluation of AZQ in metastatic breast cancer.

Abstract

Thirty-three patients with metastatic breast cancer who have failed prior combination chemotherapy including adriamycin, cyclophosphamide, 5-fluorouracil and methotrexate, were treated with AZQ given on a 5-day I.V. schedule repeated every 4 weeks. The starting doses were 6 or 8 mg/m2/day for poor- and good-risk patients, respectively. There were two partial responses among 29 evaluable patients. Both had soft tissue and/or lymph node involvement. Six patients had stable disease. Myelosuppression, predominantly thrombocytopenia, was dose-limiting. Other toxicities were mild, including nausea, vomiting, anorexia, diarrhea, stomatitis, and malaise. Our results indicate that AZQ given on the 5-day schedule is unlikely to be effective in the treatment of refractory breast cancer.

• Authors: H Y Yap, A Y Bedikian, F C Schell, G R Blumenschein, G P Bodey
• Journal: American journal of clinical oncology (Am J Clin Oncol) Vol. 6 Issue 1 Pg. 31-3 (Feb 1983) ISSN: 0277-3732 [Print] United States
• PMID: 6837505 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• Aziridines
• Azirines
• Benzoquinones
• diaziquone

Topics

• Adult
• Aged
• Antineoplastic Agents (therapeutic use)
• Aziridines (therapeutic use, toxicity)
• Azirines (therapeutic use)
• Benzoquinones
• Blood Cell Count
• Breast Neoplasms (drug therapy)
• Drug Evaluation
• Female
• Humans
• Middle Aged
• Neoplasm Metastasis